[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100600596":3},{"organization":4,"armGroups":7,"interventions":21,"overallOfficials":40,"centralContacts":44,"locations":50,"responsibleParty":70,"collaborators":27,"id":72,"slug":27,"hasResults":73,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":27,"eligibilityCriteria":77,"healthyVolunteers":73,"sex":78,"minAge":79,"maxAge":80,"enrollmentInfo":81,"targetDuration":27,"studyType":84,"phases":85,"briefSummary":87,"conditions":88,"keywords":27,"overallStatus":53,"whyStopped":27,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":99},{"fullName":5,"class":6},"Suzhou Zelgen Biopharmaceuticals Co.,Ltd","INDUSTRY",[8,16],{"label":9,"type":10,"description":11,"interventionNames":12},"Text group","EXPERIMENTAL","ZG005+Gemcitabine +Cisplatin",[13,14,15],"Drug: ZG005","Drug: Gemcitabine","Drug: Cisplatin",{"label":17,"type":10,"description":18,"interventionNames":19},"Control group","Tislelizumab+Gemcitabine+Cisplatin",[20,14,15],"Drug: Tislelizumab",[22,28,32,36],{"type":23,"name":24,"description":25,"armGroupLabels":26,"otherNames":27},"DRUG","ZG005","ZG005 20 mg\u002Fkg IV Q3W",[9],null,{"type":23,"name":29,"description":30,"armGroupLabels":31,"otherNames":27},"Tislelizumab","Tislelizumab 200mg IV Q3W",[17],{"type":23,"name":33,"description":34,"armGroupLabels":35,"otherNames":27},"Gemcitabine","Gemcitabine 1000mg\u002Fm\\^2 Q3W. Gemcitabine will be administered on D1\u002FD8 in every three weeks cycle.",[17,9],{"type":23,"name":37,"description":38,"armGroupLabels":39,"otherNames":27},"Cisplatin","Cisplatin 25mg\u002Fm\\^2 Q3W. Cisplatin will be administered on D1\u002FD8 in every three weeks cycle.",[17,9],[41],{"name":42,"affiliation":5,"role":43},"Jason Wu","STUDY_CHAIR",[45],{"name":46,"role":47,"phone":48,"phoneExt":27,"email":49},"Bo Liu","CONTACT","+86-0512-57309965","liub@zelgen.com",[51],{"facility":52,"status":53,"city":54,"state":55,"zip":56,"country":57,"countryCode":58,"cosmosGeoPoint":59,"geoPoint":64,"contacts":65},"The First Affiliated Hospital of University of Science and Technology of China","RECRUITING","Hefei","Anhui","230001","China","CN",{"type":60,"coordinates":61},"Point",[62,63],117.28083,31.86389,{"lat":63,"lon":62},[66,68],{"name":67,"role":47,"phone":27,"phoneExt":27,"email":27},"Lianxin Liu",{"name":67,"role":69,"phone":27,"phoneExt":27,"email":27},"PRINCIPAL_INVESTIGATOR",{"type":71,"investigatorFullName":27,"investigatorTitle":27,"investigatorAffiliation":27,"oldNameTitle":27,"oldOrganization":27},"SPONSOR","100600596",false,"NCT07099547","Study of ZG005 in Combination With Platinum-Based Chemotherapy in Participants With Advanced Biliary Tract Carcinoma","A Study to Evaluate the Efficacy and Safety of ZG005 in Combination With Platinum-Based Chemotherapy as First-Line Treatment in Participants With Advanced Biliary Tract Carcinoma","Inclusion Criteria:\n\n* Fully understand the study and voluntarily sign the informed consent form.\n* Subjects with a histopathological or cytologically diagnosis of Gallbladder cancer.\n* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.\n* Life expectancy of at least 3 months.\n\nExclusion Criteria:\n\n* Participants were deemed unsuitable for participating in the study by the investigator for any reasons.","ALL","18 Years","75 Years",{"count":82,"type":83},60,"ESTIMATED","INTERVENTIONAL",[86],"PHASE2","This is a randomized, open-label, phase II study evaluating first-line treatment for advanced gallbladder cancer. It aims to assess the efficacy, safety, pharmacokinetics, and immunogenicity of the ZG005 in Combination with gemcitabine and cisplatin as first-line therapy in Participants with advanced gallbladder cancer.",[89],"Biliary Tract Carcinoma","2026-04-27",{"date":92,"type":93},"2026-05-01","ACTUAL",{"date":95,"type":93},"2025-12-02",{"date":97,"type":83},"2027-12",{"name":5,"class":6},1]